Joanna Shields, BenevolentAI CEO (Andreas Gebert/picture-alliance/dpa/AP Images)

Af­ter nab­bing two AI-gen­er­at­ed mol­e­cules, As­traZeneca re­turns to Benev­o­len­tAI with new col­lab­o­ra­tion

Rough­ly three years ago, As­traZeneca teamed up with Lon­don’s Benev­o­len­tAI to bring new drugs in­to its port­fo­lio us­ing the biotech’s AI and ma­chine learn­ing ca­pa­bil­i­ties. Now that the orig­i­nal deal has borne fruit, the two com­pa­nies are re-up­ping their col­lab­o­ra­tion.

As­traZeneca and Benev­o­len­tAI will work to­geth­er in two more dis­ease ar­eas: sys­temic lu­pus and heart fail­ure, the com­pa­nies an­nounced Thurs­day. It’s a three-year part­ner­ship that comes af­ter two can­di­dates dis­cov­ered by Benev­o­len­tAI for chron­ic kid­ney dis­ease and id­io­path­ic pul­monary fi­bro­sis were nom­i­nat­ed to As­traZeneca’s port­fo­lio last year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.